M Bibl

Summary

Country: Germany

Publications

  1. ncbi CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
  2. doi CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
    Mirko Bibl
    Klinik fur Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universitat Duisburg Essen, Essen, Germany
    Proteomics Clin Appl 2:1548-56. 2008
  3. doi Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review
    Mirko Bibl
    Klinik fur Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universitat Duisburg Essen, Essen, Germany
    Dement Geriatr Cogn Disord 25:256-65. 2008
  4. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
  5. ncbi Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Mol Psychiatry 12:671-80. 2007
  6. ncbi Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    J Neural Transm 114:621-8. 2007
  7. ncbi CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    J Neural Transm 113:1771-8. 2006
  8. ncbi Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
    J Wiltfang
    Department of Psychiatry, University of Gottingen, Gottingen, Germany
    J Neurochem 81:481-96. 2002
  9. ncbi Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease
    B Mollenhauer
    Department of Neurology, Georg August University, Goettingen, Germany
    J Neural Transm 112:933-48. 2005
  10. doi [New perspectives in the laboratory diagnosis of dementia]
    M Bibl
    Klinik fur Psychiatrie und Psychotherapie, Rheinische Kliniken, Universitat Duisburg Essen, Virchowstrasse 174, 45147, Essen
    Nervenarzt 79:139-46; quiz 147-8. 2008

Detail Information

Publications29

  1. ncbi CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
    ..Their distinct molecular phenotypes support the view of different pathophysiological pathways for each of these neurodegenerative diseases...
  2. doi CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
    Mirko Bibl
    Klinik fur Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universitat Duisburg Essen, Essen, Germany
    Proteomics Clin Appl 2:1548-56. 2008
    ..Identifying disease-specific binding properties of affected Aβ carriers may elucidate pathogenic aspects and open up a novel field for therapeutic approaches...
  3. doi Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review
    Mirko Bibl
    Klinik fur Psychiatrie und Psychotherapie der Rheinischen Kliniken Essen, Universitat Duisburg Essen, Essen, Germany
    Dement Geriatr Cogn Disord 25:256-65. 2008
    ..The study evaluated the patterns of cerebrospinal fluid (CSF), amyloid-beta (Abeta) peptides, total tau and phospho-tau among Alzheimer's disease (AD) and vascular dementias (VAD)...
  4. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
    ..From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD...
  5. ncbi Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Mol Psychiatry 12:671-80. 2007
    ..CSF Abeta peptides may reflect disease-specific impact of distinct neurodegenerative processes on Abeta peptide metabolism and represent a potential diagnostic biomarker for AD, FTD and DLB...
  6. ncbi Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    J Neural Transm 114:621-8. 2007
    ..Moreover, independent methods of measurement should be applied to CSF Abeta1-38...
  7. ncbi CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies
    M Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    J Neural Transm 113:1771-8. 2006
    ..Combined evaluation of these biomarkers provides a reasonable accuracy for differential diagnosis of AD and DLB...
  8. ncbi Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation
    J Wiltfang
    Department of Psychiatry, University of Gottingen, Gottingen, Germany
    J Neurochem 81:481-96. 2002
    ..The severity of dementia was significantly correlated to the fractional Abeta peptide pattern but not to the absolute Abeta peptide concentrations...
  9. ncbi Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease
    B Mollenhauer
    Department of Neurology, Georg August University, Goettingen, Germany
    J Neural Transm 112:933-48. 2005
    ..Follow-up CSF analyses are of limited value for the differentiation of AD and DLB. We conclude that more specific markers have to be established for the differentiation and follow-up of these diseases...
  10. doi [New perspectives in the laboratory diagnosis of dementia]
    M Bibl
    Klinik fur Psychiatrie und Psychotherapie, Rheinische Kliniken, Universitat Duisburg Essen, Virchowstrasse 174, 45147, Essen
    Nervenarzt 79:139-46; quiz 147-8. 2008
    ..The lumbar puncture is therefore increasingly becoming part of the clinical routine diagnosis of demential processes and has, to some extent, far-reaching consequences. In this article, we discuss some of the important aspects...
  11. ncbi Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Jens Wiltfang
    Department of Psychiatry, University Erlangen Nurnberg, Germany
    Ann Neurol 54:263-7. 2003
    ..We conclude that the immunoblot shows disease-specific CSF Abeta peptide patterns in CJD and AD and suppose that measurement of the Abeta peptide pattern seems to be a promising diagnostic tool in the differential diagnosis of dementias...
  12. doi Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease
    Volker Welge
    Klinik fur Psychiatrie und Psychotherapie, Universitat Duisburg Essen, Rheinische Kliniken Essen, Essen, Germany
    J Neural Transm 116:203-12. 2009
    ..The ratio Abeta1-42/Abeta1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker...
  13. ncbi Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides
    Mirko Bibl
    Department of Psychiatry, University of Gottingen, Gottingen, Germany
    Electrophoresis 25:2912-8. 2004
    ..Remarkably, Abeta-SDS-PAGE/immunoblot measured threefold higher levels of Abeta1-42 in CSF than Abeta1-42-ELISA. In summary, our results indicate carrier-mediated epitope masking of Abeta1-42...
  14. doi Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes
    Juan Manuel Maler
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Schwabachanlage 6, D 91054 Erlangen, Germany
    Brain Behav Immun 22:1044-8. 2008
    ..Thus, mononuclear phagocytes might be one source of the N-truncated Abeta peptides regularly found in human plasma and are less likely to contribute substantially to plasma Abeta(1-42)...
  15. ncbi Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy PL, TWG, JMM, JK, JW, University of Erlangen Nuremberg, Erlangen, Germany
    Biol Psychiatry 55:524-30. 2004
    ..The advent of new therapeutic avenues for Alzheimer's disease (AD) calls for an improved early and differential diagnosis...
  16. ncbi Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Neurodegener Dis 4:366-75. 2007
    ..Heart-type fatty acid-binding protein (H-FABP) was recently discovered in CSF and serum of patients with neurodegenerative diseases...
  17. ncbi Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Mol Neurosci 23:115-22. 2004
    ..The current literature regarding the physiological and pathological role of phosphorylated Tau proteins is reviewed, as well as the role of these proteins as promising biomarkers in the diagnosis of neurodegenerative disorders...
  18. ncbi Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load
    Jens Wiltfang
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Erlangen, Germany
    J Neurochem 101:1053-9. 2007
    ..We conclude that the amyloid beta concentration ratio should replace the 'raw' concentrations of corresponding A beta peptides to improve reliability of the neurochemical dementia diagnosis...
  19. ncbi Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Erlangen, Germany
    Neurobiol Aging 29:812-8. 2008
    ..9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance...
  20. ncbi Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Department of Neurology, Georg August University Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:164-70. 2005
    ..We conclude that more specific markers have to be established for the differentiation of these diseases...
  21. ncbi Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Gottingen, Gottingen, Germany
    Dement Geriatr Cogn Disord 19:376-82. 2005
    ..However, there is a special interest in finding biochemical markers to monitor disease progression for differential diagnosis and treatment...
  22. ncbi Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies
    Brit Mollenhauer
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Chem Lab Med 44:192-5. 2006
    ..We conclude that more specific markers have to be established to differentiate between these diseases...
  23. ncbi Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006
    ..These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD...
  24. ncbi Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases
    Petra Steinacker
    Department of Neurology, University Hospital, Robert Koch Str 40, 37075 Goettingen, Germany
    Neurosci Lett 370:36-9. 2004
    ..Our results suggest that H-FABP might be a useful biomarker for the differentiation between the dementias examined if levels in CSF and serum are determined in parallel...
  25. ncbi International quality control survey of neurochemical dementia diagnostics
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Erlangen, Germany
    Neurosci Lett 409:1-4. 2006
    ..Although the results of this quality control survey are promising, the quality of measurements has to be further optimized...
  26. ncbi Electrophoretic separation of amyloid beta peptides in plasma
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, Molecular Neurobiology Lab, University of Erlangen Nuernberg, Erlangen, Germany
    Electrophoresis 25:3336-43. 2004
    ..Our method can be used to investigate the significance of plasma Abeta peptides in neurodegenerative disorders, and to monitor the efficiency of drugs with beta/gamma-secretase inhibitory potency...
  27. doi Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics
    Mirko Bibl
    Expert Rev Proteomics 5:153-6. 2008
  28. ncbi Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides
    Piotr Lewczuk
    Clin Chem 52:332-4. 2006
  29. ncbi Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
    Lukas Cepek
    Department of Neurology, University of Ulm, Ulm, Germany
    Dement Geriatr Cogn Disord 23:22-8. 2007
    ..We conclude that this proteomic approach can differentiate CJD from other diseases and may serve as a model for other neurodegenerative diseases...